"Gilead wins positive European approval opinion for twice-yearly HIV injection" was originally created and published by ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...

Gilead officials lauded the FDA's approval of lenacapavir, which has been studied and developed over nearly two decades. "We now have a very real opportunity to end the HIV epidemic," said Daniel ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

Several of the events took place at ‘upscale restaurants’ in San Francisco, at costs of up to $163 per person, according to ...

Gilead is prioritizing registering the drug in 18 countries with high HIV incidence rates, including Ethiopia, Kenya, Mozambique, Nigeria, Rwanda, South Africa, Uganda, Zimbabwe, Philippines ...

This photo provided by Gilead Sciences shows a vial of the company’s HIV prevention medication, Yeztugo, (lenacapvir) at a manufacturing facility in La Verne, Calif., in June 2025.